{"id":"carboplatin-pemetrexed-and-bevacizumab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carboplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription. Pemetrexed's inhibition of thymidylate synthase and other enzymes leads to a decrease in DNA synthesis and cell proliferation. Bevacizumab's binding to VEGF-A prevents the interaction with its receptor, thereby inhibiting the signaling pathways that promote angiogenesis.","oneSentence":"Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell replication. Pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:23.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer"}]},"trialDetails":[{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07420439","phase":"PHASE2","title":"Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-05-15","conditions":"Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)","enrollment":108},{"nctId":"NCT04837716","phase":"PHASE1","title":"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT06783647","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-06-11","conditions":"Advanced Solid Tumour","enrollment":230},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT03762018","phase":"PHASE3","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-30","conditions":"Pleural Mesothelioma Malignant Advanced","enrollment":401},{"nctId":"NCT06839105","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-02-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","enrollment":214},{"nctId":"NCT04042558","phase":"PHASE2","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2019-09-26","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation","enrollment":150},{"nctId":"NCT04512430","phase":"PHASE2","title":"Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients","status":"TERMINATED","sponsor":"Fundación GECP","startDate":"2020-12-02","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":4},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT04245085","phase":"PHASE2","title":"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2020-09-29","conditions":"EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC","enrollment":95},{"nctId":"NCT03872661","phase":"PHASE2","title":"Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Lung Cancer Stage III","enrollment":36},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04973293","phase":"NA","title":"Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-10-01","conditions":"Lung Neoplasm Malignant","enrollment":20},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT04322578","phase":"PHASE2","title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-03-24","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06334757","phase":"PHASE2","title":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-05-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT05930665","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Pleural Mesothelioma","enrollment":38},{"nctId":"NCT05329025","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-06-01","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT05812534","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2023-12","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":36},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT03991403","phase":"PHASE3","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":228},{"nctId":"NCT05267366","phase":"PHASE2","title":"Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2022-02-01","conditions":"PFS, OS","enrollment":117},{"nctId":"NCT01705184","phase":"PHASE2","title":"Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":120},{"nctId":"NCT03713944","phase":"PHASE2","title":"Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Nasser Hanna","startDate":"2018-11-15","conditions":"NSCLC Stage IV, NSCLC, Recurrent","enrollment":30},{"nctId":"NCT05675033","phase":"PHASE2","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-01-10","conditions":"Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor","enrollment":50},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT05334277","phase":"PHASE2","title":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-06","conditions":"Non-small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05507606","phase":"PHASE2","title":"Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT00456261","phase":"PHASE2","title":"First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2007-03","conditions":"Lung Cancer","enrollment":110},{"nctId":"NCT02743923","phase":"PHASE3","title":"Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-04","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":203},{"nctId":"NCT05132413","phase":"PHASE3","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer","enrollment":561},{"nctId":"NCT04405674","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT00402883","phase":"PHASE2","title":"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-11","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT00948675","phase":"PHASE3","title":"Study of Participants With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":361},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT00533429","phase":"PHASE2","title":"Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT01633970","phase":"PHASE1","title":"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-07-11","conditions":"Cancer","enrollment":240},{"nctId":"NCT04517526","phase":"PHASE2","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-11-01","conditions":"Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT","enrollment":60},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT01063283","phase":"NA","title":"Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-03","conditions":"Advanced Non-squamous Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT00234052","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-07-28","conditions":"Lung Cancer","enrollment":51},{"nctId":"NCT01263782","phase":"PHASE2","title":"BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05-17","conditions":"Lung Cancer","enrollment":64},{"nctId":"NCT03647956","phase":"PHASE2","title":"Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-10-01","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation","enrollment":40},{"nctId":"NCT00614822","phase":"PHASE2","title":"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Christiana Care Health Services","startDate":"2007-11","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT01344824","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-03","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT00604461","phase":"PHASE1, PHASE2","title":"Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-10","conditions":"Mesothelioma","enrollment":13},{"nctId":"NCT00798603","phase":"PHASE2","title":"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2008-12","conditions":"Lung Cancer","enrollment":65},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00974584","phase":"PHASE1","title":"A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-10","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":65},{"nctId":"NCT01301716","phase":"PHASE1","title":"A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-09","conditions":"Solid Cancers","enrollment":75},{"nctId":"NCT02930954","phase":"PHASE2","title":"Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Caicun Zhou","startDate":"2016-11","conditions":"Non-small-cell Lung Cancer","enrollment":180},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00766246","phase":"PHASE2","title":"Phase II Avastin Trial for Stage IIIB/IV NSCLC","status":"TERMINATED","sponsor":"Pharmatech","startDate":"2008-10","conditions":"Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":125},{"nctId":"NCT00976456","phase":"PHASE3","title":"Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"PD Dr. med. Wolfgang Schuette","startDate":"2009-09","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":271},{"nctId":"NCT00762034","phase":"PHASE3","title":"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":939},{"nctId":"NCT00892710","phase":"PHASE2","title":"Trial of Poor Performance Status Patients (ToPPS)","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-06","conditions":"Non Small Cell Lung Cancer","enrollment":172},{"nctId":"NCT01588704","phase":"PHASE2","title":"Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Si-Yu Wang","startDate":"2012-04","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT01700400","phase":"PHASE1","title":"Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer","status":"COMPLETED","sponsor":"Cancer Research and Biostatistics Clinical Trials Consortium","startDate":"2012-09","conditions":"Non Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT01303926","phase":"PHASE3","title":"Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2010-01","conditions":"Non-squamous Nonsmall Cell Neoplasm of Lung","enrollment":118},{"nctId":"NCT00407459","phase":"PHASE2","title":"Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Armando Santoro, MD","startDate":"2007-09","conditions":"Mesothelioma","enrollment":77},{"nctId":"NCT00254319","phase":"PHASE2","title":"Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"The Cooper Health System","startDate":"","conditions":"Untreated Advanced Non-Small Cell Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paraplatin","Alimta","Avastin"],"phase":"phase_2","status":"active","brandName":"Carboplatin, Pemetrexed and Bevacizumab","genericName":"Carboplatin, Pemetrexed and Bevacizumab","companyName":"Christiana Care Health Services","companyId":"christiana-care-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell replication. Pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing angiogenesis. Used for Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}